chan A, Stanhope KJ, Critchley DJ, et al. (1996) Electrophysiological, biochemical,
neurohormonal and behavioral studies with WAY-100635, a potent, selective and
silent 5-HT1A receptor antagonist. Behav Brain Res 73:337–353.
Forster EA, Cliffe IA, Bill DJ, Dover GM, Jones D, Reilly Y, and Fletcher A (1995) A
pharmacological profile of the selective silent 5-HT1A receptor antagonist, WAY- 100635. Eur J Pharmacol 281:81– 88.
Francis PT, Sims NR, Proctor AW, and Bowen DM (1993) Cortical pyramidal neuron
loss may cause glutamatergic hypoactivity and cognitive impairment in Alzheimer's disease. J Neurochem 60:1589 –1604.
Gozlan H, El Mestikawy S, Pichat L, Glowinski J, and Hamon M (1983) Identification of presynaptic serotonin autoreceptors using a new ligand: 3H-PAT. Nature
(Lond) 305:140 –142.
Greuel JM and Glaser T (1992) The putative 5-HT1A receptor antagonists NAN-190
and BMY 7378 are partial agonists in the rat dorsal raphe nucleus in vitro. Eur
J Pharmacol 211:211–219.
Grunschlag CR, Haas HL, and Stevens DR (1997) 5-HT inhibits lateral entorhinal
cortical neurons of the rat in vitro by activation of potassium channel-coupled
5-HT1A receptors. Brain Res 770:10 –17.
Harder JA, Baker HF, and Ridley RM (1998) The role of the central cholinergic
projections in cognition: implications of the effects of scopolamine on discrimination learning by monkeys. Brain Res Bull 45:319 –326.
Harder JA, Maclean CJ, Alder JT, Francis PT, and Ridley RM (1996) The 5-HT1A
antagonist, WAY-100635, ameliorates the cognitive impairment induced by fornix
transection in the marmoset. Psychopharmacology 127:245–254.
Harder JA and Ridley RM (2000) The 5-HT1A antagonist, WAY-100635, alleviates
cognitive impairments induced by dizocilpine (MK-801) in monkeys. Neuropharmacology 39:547–552.
Hernandez L, Tucci S, Gusman N, and Paez X (1993) In vivo monitoring of glutamate
in the brain by microdialysis and capillary electrophoresis with laser-induced
fluorescence detection. J Chromatogr A 652:393–398.
Jarrard LE (1993) On the role of the hippocampus in learning and memory in the rat.
Behav Neural Biol 60:9 –26.
Johansson L, Sohn D, Thorberg S-O, Jackson DM, Kelder D, Larsson L-G, Re ́nyi L,
Ross SB, Wallsten C, Eriksson H, et al. (1997) The pharmacological characterization of a novel selective 5-hydroxytryptamine1A receptor antagonist, NAD-299.
J Pharmacol Exp Ther 283:216 –225.
Kelleher RT, Morse WH, and Herd JA (1972) Effects of propranolol, phentolamine
and methyl atropine on cardiovascular function in the squirrel monkey during
behavioral experiments. J Pharmacol Exp Ther 182:204 –217.
Kowall NW and Beal MF (1991) Glutamate-, glutaminase- and taurineimmunoreactive neurons develop neurofibrillary tangles in Alzheimer's disease.
Ann Neurol 29:162–167.
Lazareno S and Birdsall NJ (1993) Pharmacological characterization of acetylcholine-stimulated [35S]-GTP gamma S binding mediated by human muscarinic
m1–m4 receptors: antagonist studies. Br J Pharmacol 109:1120 –1127.
Lowry OH, Rosenbrough NJ, Farr AL, and Randall RJ (1951) Protein measurements
with folin phenol reagent. J Biol Chem 193:265–275.
Maragos WF, Greenamyre T, Penney JB Jr, and Young AB (1987) Glutamate
dysfunction in Alzheimer's disease: a hypothesis. Trends Neurosci 10:65– 67.
Matsuyama S, Nei K, and Tanaka C (1996) Regulation of glutamate release via
NMDA and 5-HT1A receptors in guinea pig dentate gyrus. Brain Res 728:175–180.
McLoughlin DM, Lucey JV, and Dinan G (1994) Central serotonergic hyperresponsivity in late-onset Alzheimer's disease. Am J Psychiatry 151:1701–1703.
Morris RG, Anderson E, Lynch GS, and Baudry M (1986) Selective impairment of
learning and blockade of long term potentiation by an N-methyl-D-aspartate
receptor antagonist, AP5. Nature (Lond) 319:774 –776.
Myhrer T (1993) Animal models of Alzheimer's Disease: glutamatergic denervations
an alternative approach to cholinergic denervation. Neurosci Behav Rev 17:195–
202.
Paule MG, Bushnell PJ, Maurissen JPJ, Wenger GR, Buccafusco JJ, Chelonis JJ,
and Elliott R (1998) Symposium overview: the use of delayed matching-to-sample
procedures in studies of short-term memory in animals and humans. Neurotoxicol
Teratol 20:493–502.
Paxinos G, Watson C, Pennisi M, and Topple A (1985) Bregma, lambda and the
interaural midpoint in stereotaxic surgery with rats of different sex, strain and
weight. J Neurosci Meth 13:139 –143.
Pedigo NW, Yamamura HI, and Nelson DL (1981) Discrimination of multiple [3H]5- hydroxytryptamine binding sites by the neuroleptic spiperone in rat brain. J Neurochem 36:220 –226.
Pitsikas N, Rigamonti AE, Cella SG, and Muller EE (2003) The 5-HT1A receptor
antagonist WAY 100635 improves rat's performance in different models of amnesia evaluated by the object recognition task. Brain Res 983:215–222.
Proctor AW, Palmer AM, Francis PT, Lowe SL, Neary D, Murphy E, Doshi R, and
Bowen DM (1988) Evidence of glutamatergic denervation and possible abnormal
metabolism in Alzheimer's Disease. J Neurochem 50:790 – 802.
Rada P, Jensen K, and Hoebel BG (2001) Effects of nicotine and mecamylamineinduced withdrawal on extracellular dopamine and acetylcholine in the rat nu- cleus accumbens. Psychopharmacology 157:105–110.
Rasmussen K, Calligaro DO, Czachura JF, Dreshfield-Ahmad LJ, Evans DC, Hemrick-Luecke SK, Kallman MJ, Kendrick WT, Leander JD, Nelson DL, et al. (2000)
The novel 5-hydroxytryptamine1A antagonist LY426965: effects on nicotine withdrawal and interactions with fluoxetine. J Pharmacol Exp Ther 294:688 –700.
Ridley RM and Baker HF (1991) A critical evaluation of monkey models of amnesia
and dementia. Brain Res Rev 16:15–37.
Ridley RM, Barefoot HC, Maclean CJ, Pugh P, and Baker HF (1999) Severe learning
impairment caused by combined immunotoxic lesion of the cholinergic projections
to the cortex and hippocampus in monkeys. Brain Res 836:120 –138.
Santucci AC and Shaw C (2003) Peripheral 8-OH-DPAT and scopolamine infused
